According to the Zhitong Finance App, Boan Biotech (06955) announced interim results for the six months ended June 30, 2026. The group obtained revenue of RMB 233 million (same unit), a year-on-year decrease of 40.77%; losses attributable to owners of the parent company were 83.09 million yuan, profit of 205.14 million yuan for the same period last year; loss of 0.13 yuan per share.
The announcement said that the decline in revenue was mainly due to expectations of the upcoming government-led centralized procurement policy.
In terms of commercialization, in January 2026, the Group's 60 mg desulumab injection (AGEMED) was approved for marketing by the National Agency for Drugs and Health Technology (AGEMED) of Bolivia. In May 2026, the Group's duracopeptide injection (Boyouping) was approved for marketing in the Macau Special Administrative Region for blood sugar control in adult type 2 diabetics. In May 2026, the Group's 120mg desumab injection (Boroga) was approved by the China Drug Administration (China Drug Administration) to treat patients with solid tumor bone metastases or multiple myeloma to delay or reduce the risk of bone-related events (SRE), including pathological fractures, spinal cord compression, and bone radiotherapy or bone surgery. This is a new indication approved by Boroga. As of the date of this announcement, the Group's five products (Boyunuo, Boyoubei, Boroga, Boyouping and Boyoujing) have been successfully listed in mainland China and other countries or regions. These products have been sold to more than 3,210 target hospitals and institutions in China. The Group has carried out a number of post-marketing clinical observational studies on these marketed products. The Group believes that with the approval of new products and new indications in mainland China and other regions or countries, the accumulation of more clinical data, wider coverage of hospitals or distribution channels, and various external collaborations with experienced partners, sales of the Group's products will continue to grow.
In terms of pipeline product development in China, in April 2026, the Phase II clinical trial application for first-line or second-line treatment of non-small cell lung cancer (NSCLC) with the anti-CD25 antibody BA1106 combined with the PD-1 inhibitor (a navuliumab biosimilar injection number BA1104) developed independently by the Group was accepted by the Drug Evaluation Center (CDE) of the China Drug Administration (CDE), and the CDE approved the phase II clinical trial application in July 2026. In May 2026, updated phase I clinical data for the ADC drug BA1301, which targets CLDN18.2, was presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. BA1301 showed encouraging efficacy signals and good safety in advanced solid tumor patients with expanded sample sizes. In July 2026, a new drug clinical trial (IND) application for BA1203, an antibody cytokine prodrug targeting the PD-1 and IL-2 pathways, was accepted by the CDE. As far as we know, BA1203 will be the first shielded PD-1/IL-2 antibody cytokine prodrug to enter clinical practice that preserves alpha subunit binding activity in China. In August 2026, the ADC drug BA1302, which targets CD228, completed the single-drug dose escalation phase (phase Ia) study in the phase I clinical trial and will advance to phase Ib dose extension testing in China. Meanwhile, the IND application for BA2201 was accepted by the CDE. In addition, another pre-clinical product, BA1304, is also close to the IND declaration stage.
In terms of overseas pipeline product development, in May 2026, biological product licensing applications (BLA) for BA6101 (desumab injection, 60mg) and BA1102 (dexumab injection, 120mg) were submitted to the US Food and Drug Administration (FDA), and these BLA were accepted by the FDA in July 2026. These BLA seek approval for all indications of the two reference drugs currently approved, namely BA6101 for osteoporosis-related treatment, and BA1102 for treatment of solid bone metastases, multiple myeloma, bone giant cell tumors, and malignant tumor-related hypercalcemia. In August 2026, the Group submitted the BLA for BA9101 (abibasip intraocular injection solution) to Brazil's National Health Supervisory Authority (ANVISA) to treat adult neovascularization (wet) age-related macular degeneration (NaMD) and diabetic macular edema (DME).